Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BON NASDAQ:BPTSY NASDAQ:HEPA NASDAQ:PBLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.35-1.5%$1.40$1.14▼$73.75$225K-0.471.80 million shs103,061 shsBPTSYBiophytis$2.00+10.8%$1.60$1.33▼$7.48$702K0.851,678 shs335 shsHEPAHepion Pharmaceuticals$0.06-12.0%$0.06$0.03▼$0.08$652K1.5287,478 shs30,072 shsPBLAPanbela Therapeutics$0.16$0.19$0.05▼$0.47$767K1.3316,444 shs592 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life+5.38%+5.38%-2.84%-9.87%-97.31%BPTSYBiophytis0.00%+10.80%+10.80%-3.85%-67.16%HEPAHepion Pharmaceuticals+2.86%+7.46%+53.19%-20.00%-99.80%PBLAPanbela Therapeutics0.00%0.00%-1.31%-35.89%-57.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals1.0751 of 5 stars0.05.00.00.02.50.00.6PBLAPanbela Therapeutics0.9506 of 5 stars0.05.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/APBLAPanbela Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$1.73 per share0.78$37.78 per share0.04BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/ABPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%N/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.022.422.32BPTSYBiophytisN/A0.41N/AHEPAHepion PharmaceuticalsN/A1.301.30PBLAPanbela TherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%BPTSYBiophytis0.05%HEPAHepion Pharmaceuticals17.24%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%BPTSYBiophytis3.70%HEPAHepion Pharmaceuticals0.06%PBLAPanbela Therapeutics0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life100167,000863,000Not OptionableBPTSYBiophytis30351,000338,000N/AHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataPBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableBON, PBLA, HEPA, and BPTSY HeadlinesRecent News About These CompaniesPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comPanbela Therapeutics (OTC:PBLA) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comHorace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPanbela Therapeutics (OTC:PBLA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | insidermonkey.comPanbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q2 2024 Financial ResultsAugust 13, 2024 | globenewswire.comIs Panbela Therapeutics Inc (PBLA) Stock a Good Investment?August 3, 2024 | aaii.comAPanbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024July 30, 2024 | globenewswire.comPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationJune 24, 2024 | globenewswire.comPanbela Therapeutics Inc. (PBLA) Insider ActivityMay 25, 2024 | nasdaq.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 17, 2024 | msn.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | uk.finance.yahoo.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 16, 2024 | finance.yahoo.comPanbela Provides Business Update and Reports Q1 2024 Financial ResultsMay 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025Palantir Stock Gains Firepower From Pentagon AI DealsBy Chris Markoch | July 29, 2025The 4 Dividend Stocks Smart Money Is Grabbing Right NowBy Thomas Hughes | July 24, 20253 Reasons the Market Can Rally, 2 Ways to Diversify If It Doesn'tBy Gabriel Osorio-Mazilli | August 5, 20253 Energy Stocks to Gain Exposure to the Carbon Capture BoomBy Leo Miller | August 16, 2025BON, PBLA, HEPA, and BPTSY Company DescriptionsBon Natural Life NYSE:BON$1.35 -0.02 (-1.46%) Closing price 04:00 PM EasternExtended Trading$1.33 -0.02 (-1.78%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Biophytis NASDAQ:BPTSY$2.00 +0.20 (+10.80%) As of 08/15/2025 02:08 PM EasternBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Hepion Pharmaceuticals NASDAQ:HEPA$0.06 -0.01 (-12.04%) As of 02:36 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Panbela Therapeutics NASDAQ:PBLA$0.16 0.00 (0.00%) As of 08/18/2025 03:30 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Home Depot Holds Gains After Narrow Q2 Misses Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? D-Wave Buying Spree: Will These Firms Be Potential Targets? Lyft's Billion-Dollar Signal: Why Wall Street Is Betting Big Can AI Defense Contracts Push Palantir Shares Higher? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access